Published in Blood on March 05, 2007
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol (2008) 1.04
Are cancer stem cells radioresistant? Future Oncol (2010) 1.01
MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica (2011) 0.97
Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle. Proc Natl Acad Sci U S A (2012) 0.94
A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood (2007) 0.85
Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy (2012) 0.82
Emerging nanotechnologies for cancer immunotherapy. Exp Biol Med (Maywood) (2016) 0.75
Nanomedicine approaches to improve cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
TEMPORARY REMOVAL: Synthetic nanovaccines for immunotherapy. J Control Release (2017) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 2.73
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood (1997) 1.96
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med (2005) 1.63
The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med (2003) 1.23
Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J Immunol (1991) 1.18
Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res (2004) 1.07
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med (2004) 1.01
Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv Drug Deliv Rev (2000) 0.99
Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther (2005) 0.96
Interleukin-2-induced small unilamellar vesicle coalescence. Biochim Biophys Acta (2001) 0.84
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science (2002) 4.45
Mammalian defensins in immunity: more than just microbicidal. Trends Immunol (2002) 3.52
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol (2013) 2.01
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med (2005) 1.63
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell (2006) 1.58
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood (2012) 1.47
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol (2011) 1.45
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell (2007) 1.45
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol (2014) 1.43
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood (2002) 1.30
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res (2008) 1.29
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood (2007) 1.26
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood (2006) 1.22
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood (2005) 1.21
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood (2012) 1.19
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood (2007) 1.18
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest (2004) 1.18
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol (2012) 1.17
Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest (2004) 1.10
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) (2011) 1.10
An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release (2011) 1.07
Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res (2004) 1.07
UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis. Haematologica (2009) 1.07
Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev (2010) 1.04
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood (2012) 1.03
Detecting patients with low skeletal bone mass. J Dent (2002) 1.03
Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood (2004) 1.03
Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population. Haematologica (2013) 1.02
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer (2008) 1.02
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res (2012) 1.02
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci (2014) 1.02
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med (2004) 1.01
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood (2011) 1.01
Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. Proteomics (2004) 1.00
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol (2010) 1.00
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol (2011) 0.99
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood (2009) 0.98
MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica (2011) 0.97
Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther (2008) 0.97
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis (2006) 0.97
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine (2007) 0.96
Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J Control Release (2006) 0.96
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet (2011) 0.96
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res (2013) 0.96
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods (2007) 0.95
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res (2008) 0.94
Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol (2013) 0.94
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood (2009) 0.93
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol (2011) 0.92
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res (2009) 0.92
Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol (2004) 0.90
A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood (2011) 0.90
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica (2002) 0.89
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk (2012) 0.88
Estimation of carrier frequencies of six autosomal-recessive Mendelian disorders in the Korean population. J Hum Genet (2011) 0.88
Uranium mining and health. Can Fam Physician (2013) 0.87
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer (2007) 0.87
In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther (2013) 0.86
Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol (2011) 0.86
PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia. Int J Cancer (2014) 0.85
Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction. Ann Lab Med (2012) 0.85
A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood (2007) 0.85
Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res (2010) 0.85
Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis. Leuk Lymphoma (2006) 0.85
Index of orthodontic treatment need as a predictor of orthodontic treatment uptake. Am J Orthod Dentofacial Orthop (2005) 0.84
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res (2011) 0.84
Therapeutic idiotype vaccines in B lymphoproliferative diseases. Expert Opin Biol Ther (2004) 0.83
A novel mutation Ala57Val of the ELA2 gene in a Korean boy with severe congenital neutropenia. Ann Hematol (2008) 0.83
Clinical and genetic analysis of a Korean family with hereditary spastic paraplegia type 3. Ann Clin Lab Sci (2010) 0.83
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica (2013) 0.83
Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines (2006) 0.83
Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol (2011) 0.83
Identification of a novel splicing mutation in the ARSA gene in a patient with late-infantile form of metachromatic leukodystrophy. Korean J Lab Med (2010) 0.82
Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res (2004) 0.82
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol (2011) 0.82
Genetic variation in CYP17A1 is associated with arterial stiffness in diabetic subjects. Exp Diabetes Res (2012) 0.82
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood (2012) 0.82
A polymorphism in the growth hormone receptor is associated with height in children with Prader-Willi syndrome. Am J Med Genet A (2011) 0.81
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin Lymphoma (2005) 0.81
Novel PANK2 gene mutations in korean patient with pantothenate kinase-associated neurodegeneration presenting unilateral dystonic tremor. Mov Disord (2010) 0.81
Hemoglobin Yamagata: hemoglobin variant detected by HbA1c test. Korean J Lab Med (2009) 0.81
Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol (2007) 0.81
The use of solubility, dialyzability, and Caco-2 cell methods to predict iron bioavailability. Int J Vitam Nutr Res (2007) 0.81
Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol (2013) 0.81
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer (2014) 0.80
Cornelia de Lange Syndrome with NIPBL gene mutation: a case report. J Korean Med Sci (2010) 0.80